Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis

Caocci G.

First

;Mulas O.

Second

;Annunziata M.;Luciano L.;Bonifacio M.;Orlandi E. M.;Pregno P.;Galimberti S.;Russo Rossi A.;Abruzzese E.;Iurlo A.;Martino B.;Sgherza N.;Binotto G.;Castagnetti F.;Gozzini A.;Fozza C.;Bocchia M.;Sicuranza A.;Stagno F.;Efficace F.;Usala E.;De Gregorio F.;Scaffidi L.;Elena C.;Pirillo F.;Barate C.;Trawinska M. M.;Cattaneo D.;Labate C.;Gugliotta G.;Molica M.;Specchia G.;La Nasa G.;Foa R.;Breccia M.

2018-01-01